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BACKGROUND AND REVIEW OF LITERATURE 
1.1 Introduction 
 
An enzyme preparation (melibiase) that hydrolyzes the disaccharide melibiose was 
first isolated in 1895 by Bau
1
 and Fischer and Lindner
2
 from bottom yeast. Bottom yeast 
are species of Saccharomyces used in the brewing industry in order to prevent foam 
formation at the top levels of the fermenter.
3
 In later years Weidenhagen, who studied the 
melibiase enzyme specificity using a variety of sugars possessing non-reducing terminal 






























R and R' can be aliphatic or aromatic groups. Usually the hydroxylic acceptor molecule, 
R'OH, is water. Based on the R and R' groups the enzyme can hydrolyze a variety of 




α-Galactosidases have been reported to occur widely in nature, such as in bacteria, 
fungi, plant seeds and tissues and animal tissues. The distribution of the enzyme and 
cellular localization has been found to vary with the organism. The Escherichia coli 
enzyme is cytoplasmic, whereas the human enzyme is lysosomal and the yeast enzyme is 
extracellular.
7
 In most organisms, α-galactosidase is found in the soluble fraction of the 
cellular extracts.  
 
Physiological significances of α-galactosidases have been widely studied. For 
example, α-galactosidases are involved in the plant kingdom for hydrolyzing the 
oligosaccharides that serve as a soluble and readily metabolizable energy reserve
8
 during 





In the past, studies with α-galactosidases have mostly been carried out using 
relatively crude enzyme extracts due to the inability of obtaining the pure enzyme. α-
Galactosidases from various sources have been isolated using conventional methods of 
extraction.
6,10
 In the cell, α-galactosidases are found to be associated with other 
glycosidases, thus making it difficult to isolate.
6
 The techniques that have been used for 
the isolation of α-galactosidases include ammonium sulphate
11-14













 and iso-electro focusing.
16
 Highly purified, homogeneous α-
galactosidases have only been isolated on a few occasions.
14
 The first crystalline form of 




The α-galactosidase enzyme has shown various potential technological and 
medicinal applications. Presently the most important industrial applications of α-
galactosidase include the beet sugar industry, soy food processing, the pulp and paper 
industry, dietary industry and animal feed processing. As for medicinal applications, α-
galactosidases are currently used in blood group transformation, treatment of Fabry's 
disease and in xenotransplantation.  
 
1.2 Industrial Applications of α-galactosidase 
1.2.1 Soy based food industry 
 
Soy based foods have become a promising nutrient supplement to overcome the 
current protein-calorie malnutrition problem.
17
 Soy milk is a low-cost substitute for dairy 
milk in developing countries and a nutritive supplement for the lactose intolerant 
population.
18
 Soy usage has been limited due to the anti-nutritional compounds that 
diminish the nutritive value and lower the acceptance of soy based products. One such 
anti-nutritional factor is flatus causing oligosaccharides.
19
 Soy beans contain 9-12% total 
sugars including 4-5% sucrose, 1-2% raffinose, 3.5-4.5% stachyose and smaller 
quantities of melibiose and verbascose.
17
 Monogastric animals including humans are 
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incapable of hydrolyzing α-galactosides
20
 (raffinose and stachyose) in soy beans that 
cause flatulence and gastrointestinal disturbance, which reduce the feed efficiency and 
consumer acceptance of those products.
21
 Due to those reasons α-galactoside-free soy 
bean products have become increasingly popular. 
 
Industrially, the α-galactoside removal is achieved by treatment of soy milk with a 
crude extract of α-galactosidase obtained from the fungus Aspergillus oryzea.
20,22
 In early 
methods, the enzyme was immobilized on polyacrylamide
23, 24
 but in novel methods the 
enzyme is immobilized on calcium alginate in the presence of glutaraldehyde which is 
used as a hardner.
20
 The use of calcium alginate has been found to be comparatively safe, 




Another related application of α-galactosidase is in the form of a dietary supplement 
to overcome flatulence, bloating and abdominal discomforts.
25
 The enzyme works in the 
digestive tract to break down legumes and cruciferous vegetables to simpler sugars 
reducing flatulence. One such dietary supplement is Beano
®
 in which the source of α-




1.2.2 Sugar beet industry  
 
From the global sugar production, 30% of the sugar is produced using sugar beet, a 
root crop which is grown in the temperate zone.
27
 In colder temperatures, raffinose 




 During the manufacture of beet sugar, which is a crystallization 
process, the raffinose content increases up to > 6% by weight.
30
 This high concentration 
of raffinose inhibits the rate of sucrose crystallization as well as modifies the sucrose 
crystals to a needle like shape that lessens the consumer acceptance.
31
 Therefore the 
removal of raffinose from the manufacturing process was economical. Over the past 
decade, mycelia containing α-galactosidase have been used commercially to hydrolyze 
raffinose into sucrose and galactose. Mortierella vinacea
30
  and Absidia greisola
32
 are 
examples of α-galactosidase containing mycelia producing fungal sources in this 
industry. 
 
1.2.3 Enzymatic conversion of blood group B to O in human erythrocytes 
 
Accidental transfusion of ABO-incompatible erythrocytes causes fatal reactions. To 
overcome this and to create a universal blood supply using enzymatic methods has been 
initiated by Goldstein and colleagues in the 1980s.
33,34
 The enzymatic conversion of 
group B red blood cells to group O red blood cells in vitro is attained by the use of α-
galactosidase from coffee beans.
35, 36
 Group B antigens differ structurally from group O 
antigen only by an addition of one terminal alpha-linked galactose residue.
37,38
 α-
Galactosidase isolated from green coffee beans has shown a high activity towards 
removing the alpha-linked galactose residue from the group B red blood cell surface.
39
 







1.2.4 Enzyme therapy for Fabry disease 
 
Fabry disease is an X-linked recessive lysosomal storage disease resulting from the 
deficiency of α-galactosidase A in human.
41, 42
 Patients with this inborn error accumulate 
globotriaosylceramide and related glycosphingolipids
43
 in lysosomal plasma and tissues 
which would eventually leads to painful neuropathy with progressive renal, 
cardiovascular,
 




Recent studies have suggested that enzyme replacement therapy for Fabry disease 
was well tolerated and more effective over the already existing treatment methods. Two 
differently produced enzyme preparations have been examined in clinical investigations. 
One enzyme, which is called Fabrazyme, is produced by Chinese hamster ovary cells 
with classic recombinant technology, and the other enzyme, known as Replagal, is 
produced by cultured human skin fibroblasts with an activated promoter of the α-
galactosidase A gene.
44
 In both studies, promising lipid substrate reductions in tissue 
biopsies have been observed. The availability of the recombinant enzyme offers the 








1.2 Escherichia coli α-galactosidase 
Mel Operon 
 
In E. coli the melibiose utilization is dependant on the melibiose operon that is 
located at 93 min on the genetic map.
45
 The mel operon consists of at least two structural 
genes, melA and melB.
45,46
 Both proteins are necessary for the metabolism of melibiose.
47
 
melA, which is the promoter proximal gene, codes for the α-galactosidase enzyme that 
hydrolyses melibiose into glucose and galactose
7
 while the melB gene codes for the 
melibiose carrier protein located on the membrane, which is involved in melibiose 
transportation into the cell.
48
 The mel operon is found to be an inducible operon 
suggesting that it could be controlled in a similar way as the well studied Lactose 
operon.
47
 Recent studies show the E. coli MelR protein is a transcription activator, which 
is essential for melibiose dependant expression of melAB genes.
49-51
 These studies also 
show that the cyclic AMP receptor protein (CRP) interacts with the melAB promoter and 
increases MelR-dependent transcription activation.
49
 However the mel operon and its 





In 1971, Burstein and Kepes reported the partial purification of α-galactosidase from 
E. coli
52
 and the cofactor requirement was studied using the crude enzyme. In 1988, the 
α-galactosidase was purified but the enzyme was found to be unstable.
53
 Even though the 
 8 
eukaryotic α-galactosidase structures and mechanisms are extensively studied, the 





2.1 Material and Methods 
2.1.1 Introduction 
 
The melA gene (Appendix 1) product is the α-galactosidase protein of 451 amino 
acids in length (Appendix 2) and has a molecular weight of 50,657 Da.
11, 14, 15
 The protein 
has a theoretical pI of 5.52
15
 and has been shown to be composed of alternating 
hydrophilic and hydrophobic regions with an average hydropathy of -0.18 which is 




α-Galactosidase belongs to the glycosyl hydrolase 4 family of enzymes (GH4).
11,15
 
GH4 family enzymes are unique in their requirement for NAD(H) and a divalent metal 
ion for activity.
54









The basic experimental outline consists of genomic DNA isolation from Escherichia 
coli, recombinant plasmid construction, melA gene expression, α-galactosidase protein 
purification, enzyme activity studies and crystallization studies.  
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2.1.2 Genomic DNA isolation from E. coli 
 
The genomic DNA was obtained from One Shot TOP10 E. coli strain (Invitrogen). 
To begin the genomic DNA isolation procedure, 5 ml of fresh Luria-Bertani (LB) liquid 
media containing 50 µg/ml ampicillin was inoculated with the above E. coli strain and 
cultured for 12 hours at 37°C with shaking (200 rpm, MaxQ 500 shaking incubator, 
Barnstead Lab-Line). A 1.5 ml sample of this culture was spun down (Marathon 
microcentrifuge, Fisher Scientific) until a compact pellet formed and the supernatant was 
discarded. The pellet was resuspended in 567 µl TE buffer (50 mM Tris-HCl pH 8.0, 10 
mM EDTA) and 30 µl of 10% SDS, followed by the addition of 3 µl of a 20mg/ml 
proteinase K solution. The mixture was incubated 1 hour at 37°C. After incubation 100 µl 
of 5 M NaCl was added and mixed thoroughly, followed by adding 80 µl of 10%CTAB 
(hexadecyltrimethyl ammonium bromide) in 0.7 M NaCl and incubated for 10 min at 
65°C. An approximate equal volume (0.7-0.8 ml) of 24:1 choloroform/isoamyl alcohol 
was added, mixed and spun for 4-5 minutes in a microcentrifuge. Afterwards, the 
aqueous, viscous supernatant was removed to a fresh microcentrifuge tube and an equal 
volume of 25:24:1 phenol/chloroform/isoamyl alcohol was added and extracted 
thoroughly and microcentrifuged for 5 min. The supernatant was transferred to a fresh 
tube and the genomic DNA was precipitated by adding 0.6 vol of isopropanol. The DNA 
was spooled out and washed with 70% ethanol and microcentrifuged for 5 minutes, and 
the resulting supernatant was decanted and the pellet was dried. The dried DNA pellet 
was re-dissolved in 100 µl TE buffer and stored in -20°C. 
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2.1.3 Recombinant plasmid construction 
 
Initially, in order to construct the recombinant plasmid with the melA insert, 
Champion pET Directional TOPO Expression vectors (Invitrogen) were used. After 
many trials and failing to isolate the desired product using the above kit for one year, the 
pET-46 EK/LIC vector kit (Novagen) was used. Those two vector kits differ from each 
other mainly at the insertion step of the PCR product into the vector. In the pET 
Directional TOPO expression system, the recombinant molecule is produced by the 
insertion of the double stranded blunt ended insert to the already produced overhangs 










pET-46 EK/LIC vectors are ligation independent and were developed for the 
directional cloning of the  polymerase chain reaction (PCR) product without the need for 
restriction enzyme digestion or ligation reactions.
56,57
 The EK/LIC vectors express the 
target protein immediately downstream of an enterokinase cleavage site so that the vector 




pET Directional TOPO insertion region 
 12 
The ligation independent cloning (LIC) method takes advantage of the 3′→5′ 
exonuclease activity of T4 DNA polymerase to create very specific 13-14 base single 
stranded overhangs in the EK/LIC vector.
58
 PCR products with complementary 




Figure 2-2. EK/LIC strategy. After amplification with primers that include the 
indicated 5' LIC extensions, the PCR insert is treated with LIC-qualified T4 DNA 






α-Galactosidase forward and reverse primers were designed using the nucleotide 
sequence provided for E. coli K-12 substr. MG1655 in NCBI database with the gene ID 
NC 000913. In order to work with the LIC system, for the forward primer, 
GACGACGACAAGAT sequence and for the reverse primer GAGGAGAAGCCCGGT 
sequence were added at the 5' ends. The final primer sequences with the melA gene were, 
forward primer 5'-GACGACGACAAGATGATGTCTGCACCCAAAATT-3', reverse 
primer 5'-GAGGAGAAGCCCGGTTTAACGGTGCAACCAACG-3') which were 
custom made by Invitrogen. 
 
2.1.4 PCR reaction and gel extraction of the PCR product  
 
The melA gene was amplified from isolated E. coli genomic DNA by PCR using the 
PTC-150 Minicycler (MJ Research). Each of the primers was diluted to the concentration 
of 20 µM before PCR setup. Each 50 µl PCR mixture consisted of 3 µl of 20 µM forward 
primer, 3 µl of 20 µM reverse primer, components of the Invitrogen AccuPrime Taq 
DNA polymerase system (5 µl of 10X AccuPrime PCR buffer II and 1.5 µl of Taq DNA 
polymerase solution), 1.5 µl of isolated genomic DNA, and 36 µl of sterilized water. The 
genomic DNA was initially denatured for 6 minutes at 95°C, annealed for 45 seconds at 
60°C and extended for 1 min 30 sec at 72°C. Thereafter, from the second to the 35th PCR 
cycle, the following steps were included: 45 seconds denaturation at 95°C, 30 seconds 
annealing at 60°C, 1 minute 30 second extension at 72°C. The final extension was done at 
72°C for 7 minutes. 
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The PCR product (~1389 bp) was loaded onto a 1% agarose gel (total of 8 lanes) 
containing 0.5 µg/ml ethidium bromide and verified through agarose gel electrophoresis 
(100 V, 2 hours, Sub-Cell GT agarose gel electrophoresis, BioRad). The bands 
coresponding to the correct size of the PCR product were visualized with UV light. 
 
 To purify the PCR product, the Invitrogen PureLink Quick Gel Extraction Kit was 
utilized. This purification procedure removes primers, nucleotides, salts, agarose, 
ethidium bromide and other impurities from the amplified DNA sample. The bands 
containing the PCR product were cut from the gel and divided into two 1.5 ml 
microcentrifuge tubes to dissolve the gel material. The Gel Solubilization Buffer (598.9 
µl) was added into the tube which contained 199.6 mg of the excised gel slice. The other 
tube contained 262.1 mg of gel slice so that 786.3 µl of Gel Solubilization Buffer was 
added. The tubes were incubated at 50°C for 15 min with mixing every 3 minutes. An 
additional 5 min incubation at 50°C was done to ensure that the gel completely dissolved.  
 
The solutions were transferred by pipette, respectively, into two Quick Gel 
Extraction Columns, which were placed onto the Wash Tubes, and centrifuged in the 
microcentrifuge for 1 min at maximum speed. The flow-through was discarded. Wash 
Buffer (700 µl) containing ethanol was added into each of the Spin Columns. After 5 min 
of incubation at room temperature, the solutions were centrifuged for 1 min at maximum 
speed, and the flow through was discarded. After one more round of centrifugation to 
assure removal of all liquid, the columns were transferred onto new 1.5 ml Recovery 
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Tubes. The Nuclease-Free water (50 µl) was then added into each of the columns, and the 
PCR products bound to the resin of the columns were eluted into the Recovery Tubes.  
 
A comparison between the PCR product and the DNA mass ladder (Invitrogen), it 
was deduced from the band intensity that the concentration of the gel purified PCR 
product was 4 ng/µl. The purified PCR product will be used with the pET-46 EK/LIC 
vector from Novagen to create the α-galactosidase recombinant protein expression 
vector. 
. 
2.1.5 T4 DNA Polymerase Treatment of the Insert 
 
T4 DNA polymerase treatment generates compatible overhangs on the PCR product. 
In order to ligate with the sticky-ends of the pET-46 EK/LIC vector, the insert has to 
contain complementary sticky ends. T4 DNA polymerase reagents available with the 
pET-46 EK/LIC vector kit (Novagen) were assembled (2 µl of 10X T4 DNA polymerase 
buffer, 2 µl of 25 mM dATP, 1 µl of 100 mM DTT, and 0.4 µl of T4 DNA polymerase 
enzyme) in a 1.5 ml micro-centrifuge tube and enough purified PCR product was added 
(14.6 µl) to obtain a total volume of 20 µl. The reaction was mixed with pipetting and 
incubated at 22°C for 30 minutes. The enzyme was heat inactivated by incubating at 
75°C for 20 minutes. The prepared insert was stored at -20°C. 
 
During the annealing procedure, 1 µl of pET-46 EK/LIC vector and 2 µl of T4 DNA 
polymerase treated insert were mixed in a 1.5 ml micro-centrifuge tube and incubated at 
 16 
22°C for 5 mins. Then, 1 µl of 25 mM EDTA was added and mixed by stirring with the 




For the transformation, NovaBlue GigaSingles Competent Cells that were provided 
with the pET46 EK/LIC vector kit were removed from the -20°C freezer and placed on 
ice for ~5 min. A 1 µl sample of the annealing reaction was added directly to the 
competent cells and gently stirred and returned to the ice. The reaction tubes were 
incubated on ice for 5 min. Tubes were transferred to a water bath at 42°C and kept 
exactly for 30 seconds without shaking to heat shock the cells to make them more 
receptive to the vector plasmid. The tubes were transferred immediately onto ice. To each 
transformation mixture, 250 µl of room temperature SOC medium (EK/LIC vector kit, 
Novagen) was added followed by incubation at 37°C while shaking at 250 rpm for 60 
min prior to plating on selective medium.  
 
Selection for transformants was accomplished by plating 150 µl of the above 
reaction mixture onto a pre-warmed (37°C) LB agar plate containing 50 µg/ml ampicillin 
with the use of a bent glass rod to spread the culture onto the plate. The plasmid 
contained a gene to encode drug resistant against ampicillin. The plates were incubated 




2.1.7 Verification of the correct recombinant plasmid 
 
From the LB/Amp agar plates, single, well-isolated colonies were picked (using 
sterile toothpicks), and each colony was used to inoculate 5 ml LB/Amp media in 15 ml 
conical bottom vials. The cultures were grown for 16 hrs at 37°C and 200 rpm. An 
aliquot (1 ml) of the overnight cell culture was mixed with 0.5 ml of a sterile 60% 
glycerol solution in a 2 ml cryo-vial and stored at -80°C for future propagation and 
maintenance of gene construct. 
 
The remaining culture was used to harvest cells with centrifugation at 4500 rpm for 
10 min at 4°C (Allegra X-15R Benchtop Centrifuge, Beckman Coulter) for the plasmid 
isolation process using the Wizard Plus SV Miniprep DNA Purification System 
(Promega). The supernatant was discarded and the pellet was resuspended completely in 
250 µl of Cell Resuspension Solution (50 mM Tris-HCl pH 7.5, 10 mM EDTA, and 100 
µg/ml RNase A) by vortexing. Afterwards, the resuspended pellet was transferred into a 
1.5 ml microcentrifuge tube and mixed with 250 µl Cell Lysis Solution (0.2 M NaOH and 
1% SDS) by inverting the tube 4 times. Partial clearing of the lysate was observed after 5 
min incubation. To quench the endonucleases and other proteins released during the lysis, 
Alkaline Protease Solution (10 µl) was added into the lysate, mixed by inverting the tube 
4 times and incubated for 5 min. After incubation, the cell solution was mixed with 350 
µl Neutralization Solution (4.09 M guanidine hydrochloride, 0.759 M potassium acetate, 
and 2.12 M glacial acetic acid) by inverting the vial 4 times for solution neutralization. 
The mixture was centrifuged (Marathon Microcentrifuge, Fisher Scientific) at maximum 
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speed for 10-30 min until the cell debris was pelleted. The cleared lysate was then 
decanted into a Spin Column, which was inserted into a 2 ml Collection Tube for the 
plasmid DNA purification. The contents in the Spin Column were centrifuged at 
maximum speed for 1 min, and the flow-through from the Collection Tube was discarded. 
The Column Wash Solution (750 µl, 60% ethanol, 60 mM potassium acetate, 8.3 mM 
Tris-HCl, 0.04 mM EDTA) was added into the Spin Column and centrifuged at 
maximum speed for 1 min, and the flow through was discarded. Ethanol will precipitate 
the plasmid DNA, which was collected by the resin of the Spin Column. The wash was 
repeated using 250 µl Column Wash Solution and centrifuged for 2 min at maximum 
speed. The Spin Column was transferred to a new 1.5 ml microcentrifuge tube. By adding 
100 µl Nuclease-Free water into the column with 1 min centrifugation at maximum 
speed, the plasmid DNA was eluted into the 1.5 ml microcentrifuge tube. The Spin 
column was discarded, and the plasmid DNA samples were stored at -20°C.  
 
To verify the presence and the concentration of the plasmid, a 1% agarose gel 
electrophoresis was carried out with 8 lanes. The expected linear plasmid size was ~ 6589 
bp. With comparison to the Mass marker, the concentration of isolated plasmids was 
determined to be 15-20 ng/µl. From the isolated plasmid samples, five samples were used 






 Figure 2-3 The restriction sites of the pET-46 EK/LIC vector. AccI restriction sites 




In the restriction enzyme analysis, AccI (Promega) was used to digest the 
recombinant plasmid twice in two different locations (on the map at positions 2492 and 
5077) for the verification of the correct insertion. In a 1.5 ml micro-centrifuge tube, 7 µl 
of sterile water, 2 µl Restriction Enzyme 10X buffer, 0.5 µl of BSA, and 0.5 µl of Acc I 
restriction enzyme (all provided by Promega) were mixed with 10 µl of 4 ng/µl DNA and 
digested for 2 hrs at 37-42°C in a water bath. After digestion, 10 µl out of the total 20 µl 
of the products were loaded onto a 0.9% agarose gel and electrophoresed at 100 V for 2 
hrs. 
 AccI (2492) 
AccI (5077) 
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The integrity of the plasmid was further checked with DNA fluorescent sequencing 
by the Recombinant DNA/Protein Resource Facility of the Biochemistry and Molecular 
Biology Department.  The T7 promoter and terminator primers, which lie on either side 
of the inserted gene and control the expression of the recombinant protein, was performed 
to confirm the melA gene was cloned into the pET-46 EK/LIC vector with the correct size 
and orientation. 
  
2.1.8 Over expression of α-galactosidase and purification  
 
The verified recombinant plasmids were transformed into E. coli BL21 Star DE3 
competent cells (Invitrogen). The BL21 Star DE3 E. coli cells are genetically engineered 
to improve T7 RNA polymerase producing mRNA stability which enhances the targeted 
protein production significantly since the targeted gene transcription promoter is T7 
based. 
 The transformants were grown in 10 ml of LB media containing 50 µg/ml 
ampicillin (Amp) at 37°C and shaking at 200 rpm overnight. The small cultures were 
used to inoculate 250 ml LB/Amp media and grown at 37°C at 200 rpm until an optical 
absorbance of the culture at 600 nm (A600) was between 0.6 and 0.8. Then the expression 
of the recombinant protein was induced by adding 1 mM isopropyl-β-D-1-
thiogalactopyranoside (IPTG; Sigma), and the temperature was decreased to 25°C. The 
bacterial culture was incubated at 25°C for 20 hrs with shaking at 200 rpm. Cells were 
harvested by centrifugation (Allegra X-15R benchtop centrifuge, Beckman Coulter) at 
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4500 rpm for 10 min at 4°C. The supernatant was discarded and the pellets were frozen at 
-20°C until needed. 
 
The cell pellet from 250 ml of culture was resuspended in 25 ml of ice-cold lysis 
buffer (40 mM Tris-HCl pH 8, 500 mM NaCl, and 0.2 mg/ml lysozyme) with votexing. 
The lysate was sonicated (Sonifier 150 Liquid processor, Branson) for 30 seconds at 
analog speed setting of “2” followed by cooling on ice for 30 seconds. Both the 
sonication and cooling steps were repeated three more times. The sonicated lysate was 
centrifuged at 3500 rpm for 50 min at 4°C until a clear supernatant was visible. α-
Galactosidase was a soluble protein, thus it will be present in the supernatant of the 
sonicated cell suspension. The centrifuged clear solution was transferred to a fresh 
conical tip centrifuged tube. 
 
For the purification of α-galactosidase, the Biologic Duo-Flow Chromatography 
System (Bio-Rad) was used. Immobilized metal affinity chromatography was used in the 
purification process. Prepackaged and precharged Ni Sepharose™ containing HisTrap™ 
HP Columns were purchased from GE Healthcare. The recombinant α-galactosidase 
contains an N-terminal poly-histidine tag, which would enable the protein to bind with 
the Ni
2+
 in the column. Since the proteins without the His tag would bind weakly or not at 
all to the Ni
2+
 column, they would be eluted first at a low imidazole concentration leaving 
the His tag containing proteins to elute at a higher imidazole concentration. 
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A considerable amount of β-lactamase protein, coded by the ampicillin resistant 
gene, was produced. A step-wise purification, where the imidazole concentration is 
varied in a step-wise manner, was done in order to minimize the impurities including β-
lactamase and to get a much purer sample of the α-galactosidase protein. A nickel(II) 
chelating column with a 5 ml bed volume was preloaded with the 25 ml of crude protein 
extract using a Model EP-1 Econo Pump (Bio-Rad) at a 1 ml/min flow rate. The 
preloaded nickel(II) column was mounted onto the Biologic Duo-Flow Chromatographic 
system for the purification and elution of the α-galactosidase. 
 
The buffers used in the purification of alpha galactosidase using the Biologic Duo-
Flow system are 40 mM Tris-HCl with 500 mM NaCl, 40 mM Tris Base with 500 mM 
NaCl, 500 mM imidazole (pH 8), and degassed water. Thorough out the purification, the 
buffer blending mode was used, which mixes the Tris solutions and the water/imidazole 
solutions separately and then mixes them together.  Furthermore, the Tris solution is 
titrated to a pH of 8. Therefore, the final solution will contain 20 mM Tris (pH 8) and 
varying amounts of imidazole from 0 to 250 mM, depending on the percentage specified 
in the program. Initial non-bound impurities were eluted using 16 ml of 5% 12.5 mM 
imidazole at the rate of 2 ml/min. Most of the unbound impurities were eluted at this 
imidazole concentration. The column was further washed using 26 ml of 25% 62.5 mM 
imidazole at the rate of 2 ml/min. Tightly bound α-galactosidase was eluted next with 40 
ml of 250 mM imidazole at the rate of 2 ml/min. After the elution of the proteins, the 
column was washed further with 10 ml of 25% 62.5 mM Imidazole at the rate of 2 
ml/min. 
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The collected fractions were verified for the presence of α-galactosidase protein 
using 15%  sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel 
electrophoresis using Mini-Protein 3 Cell electrophoresis apparatus (Bio Rad) with a 
Precision Plus Protein Standards marker (Bio Rad). 
 
The fractions containing the α-galactosidase were collected and further purified 
using a desalting column (HiPrep 26/10 Desalting GE Healthcare). In the desalting 
process 60 ml of 20 mM Tris HCl at pH 7 was used at the rate of 3 ml/min. Eluted 
fractions were analyzed using 15% SDS PAGE gels. The bands of the resulting gel were 
further analyzed using Matrix-ssisted laser desorption ionization mass spectrometry time of 
flight (MALDI-TOF) mass spectroscopy at the recombinant DNA/ Protein Resource 
Facility of the Biochemistry and Molecular Biology Department. 
 
The purified protein fractions were concentrated to 1.5 ml using a 20 ml centricon 
with 10,000 MW cut off (Vivaspin, Vivascience) with centrifugation at 3000 rpm and 
4°C. The final concentration was determined by the Bradford assay using bovine serum 
albumin as the standard. In the Bradford assay, Coomassie brilliant Blue G-250 binds to 
the protein and produce absorbance at 600 nm. The protein concentration is proportional 
to the absorbance and can be calculated using a calibration plot of absorbance vs. 
concentration. 
 







 Furthermore activity of the enzyme appeared to be maximum in reducing 
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 (DTT) were added and 
the activity of the enzyme was checked as suggested in the literature.  
 
To the purified α-galactosidase (50 µg/ml), 0.5 mM Mn2+, 0.9 mM NAD+ and 10 
mM DTT were added and the volume was adjusted to 450µl using 20 mM Tris HCl pH 7, 
mixed well and incubating for 5 min at room temperature. A 50 µl sample of 10 mM p-
nitrophenyl-α-D-galactopyranoside (Sigma) was added and incubated at room 








X-ray crystallography is widely used in the study of proteins at atomic resolution. In 
order to solve the structure of the protein, X-ray diffraction data of a well grown, good 
quality single crystal must be obtained.
62,63
 The most common setup to grow protein 
crystals is by the hanging drop technique. The hanging drop method is commonly used in 









    
Figure 2-4. A diagram of the hanging drop vapor diffusion method A) Vacuum 
grease sealed experimental set up with a droplet on an inverted coverslip. B) A 




 In the hanging drop method, bringing a protein solution to a saturation point is 
controlled by the vapor diffusion with the use of precipitating agents. A small droplet 
(~5µl) of protein containing buffer and precipitating agent is suspended on a glass or 
microscope coverslip over a well containing a much larger volume (~300 – 1000 µl) of 
the same buffer and precipitation agent solution with a large osmolarity. Over time, a net 
evaporation of the water from the protein sample droplet and a net condensation in the 
reservoir solution equalize the osmolarities of the two solutions. The evaporation of water 
from the protein sample droplet results in lowering the solubility of protein and the 
precipitating agent concentration that would induce the formation of protein crystals. 






a single protein crystal with good diffraction quality involves the optimization of many 
chemical and physical parameters. 
 
Crystallization trials were done using the crystal screen kits provided by Hampton 
Research and ammonium sulfate percent saturation series as the precipitating agent.
62
 
The hanging drop vapor diffusion method was used with purified α-galactosidase at 1.2 
mg/ml and 3 mg/ml concentration in 20 mM Tris-HCl (pH 7), 0.5 mM Mn
2+
, 0.9 mM 
NAD
+
, and 10 mM DTT with the crystal screening kits HR2-110 containing 50 
conditions and HR2-112 containing 48 conditions (Hampton Research) at room 
temperature and 4°C. In the Linbro plates, the well solution had 700 µl of the crystal 
screen solution while the hanging drop contained 2 µl of the well solution and 2 µl of 
the protein solution. 
With the ammonium sulfate as the precipitating agent, the initial investigations for 
the effect of % salt concentration at 15%, 20%,25%,30%,35% and 40% were checked in 
the pH range of 3.5- 9.0 at 0.5 increments. 
 
2.2 Results and Discussion 
 
After failing many times with the pET100 D-TOPO vector system (Invitrogen), the 
construction of the recombinant molecule with α-galactosidase insert was successfully 
obtained using the pET-46 EK/LIC vector system (Novagen). The initial failure with the 
Invitrogen system was attributed to the fact; as the company explained, “the presence of 
some background” in the particular batch that the first vector was produced. However, 
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the correct recombinant molecule was never obtained after many repeated trials with 
newly bought champion pET expression system. The failure to produce the correct 
recombinant molecule for α-galactosidase with TOPO system could be attributed to the 
fact that earlier mentioned insertion mechanism was not successful with the melA gene 
insert.  A use of an exonuclease to produce 3' overhangs on the PCR product might have 
been helpful with using the TOPO system for the construction of the recombinant 
molecule. 
 
The PCR fragment of the melA gene is ~ 1356 bp in length. (Figure 2-5). After the 
gel extraction of the PCR fragment the concentration of the purified PCR insert was 













Figure 2-5. Size verification of the PCR products using 1% agarose gel stained with 
ethidium bromide. First and the last lanes show the size markers. 
 
 






                           
 
Figure 2-6. Verification of the insert after gel extraction and determination of the 
concentration using a 1% agarose gel. First lane shows the 1 kb ladder and the last 
lane shows the mass-marker used for the intensity based concentration 
determination. 
 
The pET-46 EK/LIC vector size is ~5200 bp and the PCR insert is ~1389 bp. 
Therefore the size of the extracted plasmids from the NovaBlue GigaSingles Competent 
Cells is ~6589 bp. The concentration of the recombinant plasmid is found to be 20 ng/µl 
by comparison to the band intensities of the molecular mass standards. (Figure 2-7). The 
isolated plasmids did not show the expected size (6589 bp) due to the supercoiled nature 
of the circular plasmids. The restriction enzyme AccI cut the plasmid twice. The plasmid 
with the insert will give two band fragments with the longer one being 4004 bp and the 
shorter one being 2585 bp, while the plasmids without the insert will give two bands of 
2615 bp and 2585 bp, which are very close in size and might be difficult to separately 










Figure 2-7 Isolated recombinant plasmid samples from NovaBlue GigaSingles cells 
on a 1% agarose gel. The concentrations of the plasmids were determined using the 




Figure 2-8 Verification of the presence of the insert in the vector on a 0.9% agarose 
gel stained with ethidium bromide. Last lane indicates the 1 kb size marker. 
 
  The restriction enzyme digestion of almost all the isolated plasmid samples gave 
two different bands with the expected sizes except in the 3
rd
 lane where an extra band 
with a size ~6500 bp is also present. This extra band could be the linearlized plasmid 








with the insert (6589bp) which is due to a single cut by the AccI restriction enzyme. The 
DNA sequencing results of the construct melA pET-46 EK/LIC matched the known DNA 
sequence for the melA gene from the NCBI database (GeneID: 948636). 
 
In the expression of the α-glactosidase using the E. coli BL21 Star DE3 cells, the 
temperature of the growing culture should be reduced to 25°C from 37°C after addition 
of IPTG in order to get the protein in the soluble fraction. Temperatures above 30°C tend 
to produce the protein in large scale but the protein ends up in the inclusion bodies. 
Addition of sugar to the growing culture does not seem to affect the protein production as 
expected and therefore all cultures were grown without any sugar in the medium. 
According to literature adding sugar to the bacterial culture may help to repress basal 
expression of T7 RNA polymerase and stabilize the pET product. 
 
The molecular weight of the α-galactosidase protein fused with the His tag is about 
53.6 kDa. The following chromatogram shows the protein purification using a nickel(II) 
column (Figure 2-9). In each chromatogram the relationship between absorbance (280 nm 
- blue line) and the time in minutes is shown. The top horizontal line shows the collected 
fraction numbers of the eluted proteins and the black line indicates the concentration of 
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Figure 2-9. Chromatogram obtained for the purification of α-galactosidase using 





Figure 2-10. A 15% SDS PAGE gel obtained after the nickel(II) column purification 
of the α-galactosidase protein. The 1
st
 lane shows the protein standards. The 2nd 
lane shows the components of the flow through and lanes 3-9 shows the α-
galactosidase corresponding to the labeled peak in the chromatogram. Due to over 
loading of the column some of the α-galactosidase were eluted with the flow through. 
 
α-galactosidase 
50 kDa  







The chromatogram obtained from the nickel(II) column chromatography indicates 
two major peaks: one arising until about 10 minutes into the purification and the second 
from 25–35 minutes (Figure 2-8). The peak around 10 minutes indicates the non-
specifically bound proteins to the Nickel(II) column that elutes at a low imidazole 
concentration. The second peak indicates the α-galactosidase protein which would only 
elute at a very high imidazole concentration due to the specific interactions between the 
nickel(II) ions and the poly-histidine tags of the protein. 
 
The 15% SDS PAGE gel with the precision plus protein standards (Bio Rad) of the 
purified α-galactosidase verified the size of the protein and the level of purification. 
(Figure 2-10) 
 
The fractions containing the purified α-galactosidase protein were collected and 
desalted with a desalting column (Figures 2-11 and 2-12). The protein analysis through 











































Figure 2-11. Chromatogram of the α-galactosidase obtained after desalting using 






Figure 2-12. A 15% SDS PAGE gel obtained after desalting the α-galactosidase 





Figure 2-13. Result from the MALDI-TOF mass spectroscopic analysis of the 
recombinant α-galactosidase. The top score was 104 for Escherichia coli α-
galactosidase for. Protein scores greater than 64 are significant (p<0.05). 
 
 
The yield of the purified protein is measured by the Bradford assay, and from 500 
ml of LB/ampicillin media, ~30 mg of α-galactosidase was produced. When the purified 
α-galactosidase was stored in 20 mM Tris HCl pH 7, the protein started degrading after 2 
weeks at 4°C and the protein did not respond to the activity assay. The freshly purified 




 and DTT were stable and active for more than 
eight weeks. However the activity of the protein sample reduced after eight weeks of 
storage in 4°C. 
 
In the crystal screening process using the Hampton Research crystal screening kits, a 
few small crystals of α-galactosidase were observed using two different crystallizing 
conditions at room temperature within 6-7 days. One of the crystallizing conditions was a 
well solution containing 0.01 M Iron(III) chloride hexahydrate, 0.1 M sodium citrate 
tribasic dehydrate (pH 5.6), 10% v/v Jeffamine M-600 (No.18, Crystal Screen 2, HR2-
112) and the other is 0.1 M HEPES (pH 7.5), 20% v/v Jeffamine M-600 (No. 31, Crystal 
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Screen 2, HR2-112). Microseeding of the crystal produced droplets were done using a cat 
whisker but did not produce any results. None of the obtained small crystals diffracted X-
rays to medium or high resolution and no data were collected to find the structure or the 
space group.  
 
One of the major problems encountered with the crystal screening process was the 
instant precipitate formation on the droplet. In some of the cases this was due to the 
presence of Mn
2+
 as a cofactor in the protein solution that would lead to precipitate when 
combined with solutions from the crystal screens. A higher concentration of the α-
galactosidase (9.2 mg/ml in 20 mM Tris HCl pH 8) seems to precipitate the protein 















α-Galactosidase is reported to occur widely in animals, plants and micro-organisms
6
 
and has shown various potential industrial and medicinal applications. X-ray crystal 
structure of the glycosylated, human α-galactosidase A, which in the defective form 
causes Fabry disease, has already determined
64
 and structural anomalies are well 
studied.
65,66
 Even though the eukaryotic α-galactosidase structures are well studied, the 
information about prokaryotic α-galactosidases are seldom available. These facts led us 
to investigate α-galactosidase structure from an abundant micro-organism Escherichia 
coli. 
 
In the research α-galactosidase producing gene (melA) from E. coli (~1356 bp) was 
successfully cloned onto a pET-46 EK/LIC vector (Novagen). This His tag bearing 
Ligation independent cloning vector of Novagen was extremely efficient in the cloning 
process and the resulting was nearly ~100%. The protein was over expressed using BL21 
Star DE3 (Invitrogen) cell line which utilizes a highly efficient T7 promoter based 
expression mechanism to over produce the targeted protein from the recombinant 
molecule.  The α-galactosidase was purified using metal ion affinity chromatography 
which utilizes nickel(II) containing His Trap columns. The initial crystallization trials 
were carried out using the purified α-galactosidase. 
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However, well grown, single crystals that would diffract X-ray were not obtained 
during this research. In the future, crystallization procedures of α-galactosidase could be 
tried using different desalting buffers in different pHs, with varying protein 
concentrations, micro-seeding of the precipitates in droplets, varying the pH of the salt or 
the precipitant and optimizing the cofactor requirements in order to obtain a well 
stabilized active α-galactosidase that might enhance the crystal formation. Another future 
consideration would be to study the enzyme kinetics of purified α-galactosidase of E.coli, 
with the cofactors. 
 
 Both structural and enzyme kinetic studies on α-galactosidase will help in the better 
understanding of the enzyme’s biological role and mechanism that would lead to future 
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Forward primer  
Reverse primer with stop codon in blue  
 
2. Amino acid sequence of α-galactosidase from E.coli 
 
MMSAPKITFI GAGSTIFVKN ILGDVFHREA LKTAHIALMD IDPTRLEESH  50 
IVVRKLMDSA GASGKITCHT QQKEALEDAD FVVVAFQIGG YEPCTVTDFE 100 
VCKRHGLEQT IADTLGPGGI MRALRTIPHL WQICEDMTEV CPDATMLNYV 150 
NPMAMNTWAM YARYPHIKQV GLCHSVQGTA EELARDLNID PATLRYRCAG 200 
INHMAFYLEL ERKTADGSYV NLYPELLAAY EAGQAPKPNI HGNTRCQNIV 250 
RYEMFKKLGY FVTESSEHFA EYTPWFIKPG REDLIERYKV PLDEYPKRCV 300 
EQLANWHKEL EEYKKASRID IKPSREYAST IMNAIWTGEP SVIYGNVRND 350 
GLIDNLPQGC CVEVACLVDA NGIQPTKVGT LPSHLAALMQ TNINVQTLLT 400 
EAILTENRDR VYHAAMMDPH TAAVLGIDEI YALVDDLIAA HGDWLPGWLH 450 
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